- Home
- PBYI vs QTRX Comparison
PBYI vs QTRX Comparison
Compare PBYI & QTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PBYI | QTRX |
|---|---|---|
| Founded | 2010 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 263.4M | 306.0M |
| IPO Year | 2011 | 2017 |
Fundamental Metrics
Financial Performance| Metric | PBYI | QTRX |
|---|---|---|
| Price | $6.00 | $4.53 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $11.33 |
| AVG Volume (30 Days) | 429.2K | ★ 574.3K |
| Earning Date | 05-07-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | $27,685,000.00 | ★ $37,632,000.00 |
| Revenue This Year | N/A | $25.45 |
| Revenue Next Year | N/A | $13.83 |
| P/E Ratio | $9.84 | ★ N/A |
| Revenue Growth | N/A | ★ 64.52 |
| 52 Week Low | $2.58 | $4.15 |
| 52 Week High | $7.68 | $8.77 |
Technical Indicators
Market Signals| Indicator | PBYI | QTRX |
|---|---|---|
| Relative Strength Index (RSI) | 42.49 | 28.08 |
| Support Level | $5.57 | $4.30 |
| Resistance Level | $6.15 | $5.56 |
| Average True Range (ATR) | 0.37 | 0.36 |
| MACD | -0.05 | -0.08 |
| Stochastic Oscillator | 33.18 | 4.71 |
Price Performance
Historical ComparisonAbout PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About QTRX Quanterix Corporation
Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.